Literature DB >> 34363343

Development and Validation of a Juvenile Spondyloarthritis Disease Flare Measure: Ascertaining Flare in Patients With Inactive Disease.

Pamela F Weiss1, Timothy G Brandon2, Meghan E Ryan3, Erin B Treemarcki4, Stephanie Armendariz5, Tracey B Wright6, Chetna Godiwala5, Matthew L Stoll7, Rui Xiao8, Daniel Lovell9.   

Abstract

OBJECTIVE: Our objective was to develop and validate a composite disease flare definition for juvenile spondyloarthritis (SpA) that would closely approximate the clinical decision made to reinitiate or not reinitiate systemic therapy after therapy de-escalation.
METHODS: Retrospective chart reviews of children with SpA who underwent systemic therapy de-escalation of biologic or conventional disease-modifying antirheumatic drugs were used to develop and validate the flare outcome. Data on independent cohorts for development (1 center) and validation (4 centers) were collected from large tertiary health care systems. Core measure thresholds and candidate disease flare outcomes were assessed using sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs), and the receiver operating characteristic (ROC) area under the curve (AUC), with physician assessment of active disease plus re-initiation of standard dose of systemic therapy as the reference standard.
RESULTS: Of the candidate definitions, clinically meaningful worsening in ≥3 of the following 5 core measures performed best: caregiver/patient assessment of well-being; physician assessment of disease activity; caregiver/patient assessment of pain, physical function, and active joint count. The ROC AUC was 0.91, PPV 87.5%, NPV 98.1%, sensitivity 82.4%, and specificity 98.7%. Cronbach's α was 0.81, signifying internal consistency, and factor analysis demonstrated that the outcome measured 1 construct. The Juvenile SpA Flare measure had face validity according to 21 surveyed pediatric rheumatologists. The Juvenile SpA Flare had an ROC AUC of 0.85, a PPV of 92.3%, and an NPV of 96.8% in the validation cohort.
CONCLUSION: There is initial support for the validity of the Juvenile SpA Flare measure as a tool to identify disease flare in juvenile SpA patients de-escalating therapy, and the measure is potentially applicable in clinical practice, observational studies, and therapeutic trials.
© 2021 American College of Rheumatology.

Entities:  

Year:  2021        PMID: 34363343      PMCID: PMC8818809          DOI: 10.1002/acr.24763

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  24 in total

1.  Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation.

Authors:  Katherine J Lee; John B Carlin
Journal:  Am J Epidemiol       Date:  2010-01-27       Impact factor: 4.897

2.  Patient-Reported Outcomes Measurement Information System Tools for Collecting Patient-Reported Outcomes in Children With Juvenile Arthritis.

Authors:  Timothy G Brandon; Brandon D Becker; Katherine B Bevans; Pamela F Weiss
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

3.  Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Authors:  Angelo Ravelli; Alessandro Consolaro; Gerd Horneff; Ronald M Laxer; Daniel J Lovell; Nico M Wulffraat; Jonathan D Akikusa; Sulaiman M Al-Mayouf; Jordi Antón; Tadej Avcin; Roberta A Berard; Michael W Beresford; Ruben Burgos-Vargas; Rolando Cimaz; Fabrizio De Benedetti; Erkan Demirkaya; Dirk Foell; Yasuhiko Itoh; Pekka Lahdenne; Esi M Morgan; Pierre Quartier; Nicolino Ruperto; Ricardo Russo; Claudia Saad-Magalhães; Sujata Sawhney; Christiaan Scott; Susan Shenoi; Joost F Swart; Yosef Uziel; Sebastiaan J Vastert; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2018-04-11       Impact factor: 19.103

4.  Development and retrospective validation of the juvenile spondyloarthritis disease activity index.

Authors:  Pamela F Weiss; Robert A Colbert; Rui Xiao; Chris Feudtner; Timothy Beukelman; Esi Morgan DeWitt; Ilaria Pagnini; Tracey B Wright; Carol A Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

5.  Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology.

Authors:  N Ruperto; A Ravelli; A Pistorio; C Malattia; S Cavuto; L Gado-West; A Tortorelli; J M Landgraf; G Singh; A Martini
Journal:  Clin Exp Rheumatol       Date:  2001 Jul-Aug       Impact factor: 4.473

6.  Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method.

Authors:  David Thissen; Yang Liu; Brooke Magnus; Hally Quinn; Debbie S Gipson; Carlton Dampier; I-Chan Huang; Pamela S Hinds; David T Selewski; Bryce B Reeve; Heather E Gross; Darren A DeWalt
Journal:  Qual Life Res       Date:  2015-06-29       Impact factor: 4.147

7.  Minimal clinically important differences of the childhood health assessment questionnaire.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Michael J Miller; Andrea Barron; Nicole Baldwin; Michael Trombley; Anne L Johnson; Angie Kress; Daniel J Lovell; Edward H Giannini
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

8.  Lack of Concordance in Interrater Scoring of the Provider's Global Assessment of Children With Juvenile Idiopathic Arthritis With Low Disease Activity.

Authors:  Janalee Taylor; Edward H Giannini; Daniel J Lovell; Bin Huang; Esi M Morgan
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-12-06       Impact factor: 4.794

9.  Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort.

Authors:  Jaime Guzman; Andrew Henrey; Thomas Loughin; Roberta A Berard; Natalie J Shiff; Roman Jurencak; Adam M Huber; Kiem Oen; Kerstin Gerhold; Brian M Feldman; Rosie Scuccimarri; Kristin Houghton; Gaëlle Chédeville; Kimberly Morishita; Bianca Lang; Paul Dancey; Alan M Rosenberg; Julie Barsalou; Alessandra Bruns; Karen Watanabe Duffy; Susanne Benseler; Ciaran M Duffy; Lori B Tucker
Journal:  J Rheumatol       Date:  2019-01-15       Impact factor: 4.666

10.  Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.

Authors:  Tamas Constantin; Ivan Foeldvari; Jelena Vojinovic; Gerd Horneff; Ruben Burgos-Vargas; Irina Nikishina; Jonathan D Akikusa; Tadej Avcin; Jeffrey Chaitow; Elena Koskova; Bernard R Lauwerys; Inmaculada Calvo Penades; Berit Flato; Maria Luz Gamir; Hans-Iko Huppertz; Juan Jose Jaller Raad; Katerina Jarosova; Jordi Anton; Marie Macku; William J Otero Escalante; Lidia Rutkowska-Sak; Ralf Trauzeddel; Patricia J Velez-Sanchez; Carine Wouters; Joseph Wajdula; Chuanbo Zang; Jack Bukowski; Deborah Woodworth; Bonnie Vlahos; Alberto Martini; Nicolino Ruperto
Journal:  J Rheumatol       Date:  2016-03-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.